Skip to main content
UploadLanguage (EN)Support
BusinessMobileSocial MediaMarketingTechnologyArt & PhotosCareerDesignEducationPresentations & Public SpeakingGovernment & NonprofitHealthcareInternetLawLeadership & ManagementAutomotiveEngineeringSoftwareRecruiting & HRRetailSalesServicesScienceSmall Business & EntrepreneurshipFoodEnvironmentEconomy & FinanceData & AnalyticsInvestor RelationsSportsSpiritualNews & PoliticsTravelSelf ImprovementReal EstateEntertainment & HumorHealth & MedicineDevices & HardwareLifestyle
Suresh Kumar Ghritlahare, profile picture
Uploaded bySuresh Kumar Ghritlahare
PPTX, PDF5,864 views

Antiarrhythmic drugs

This document discusses antiarrhythmic drugs, which are used to treat irregular heart rhythms. It describes the different classes of antiarrhythmic drugs including membrane stabilizers, beta blockers, drugs that widen the action potential, and calcium channel blockers. The document provides examples of drugs in each class and explains their mechanisms of action, such as blocking sodium or calcium channels. It also discusses the pharmacokinetics of lidocaine and the uses and adverse effects of antiarrhythmic drugs.

Health & Medicine◦
Downloaded 46 times
Antiarrhythmic Drugs Suresh Kumar Ghritlahare Assist. Professor SRU, Raipur, (C.G.)
Antiarrhythmic Drugs Arrhythmia: • The cardiac arrhythmias are cause by disturbance conduction of impulse through myocardial cell. • Arrhythmia is irregularities in cardiac rhythm due to disorder of impulse formation & impulse conduction. • Disturbed impulse formation, irregular discharge of impulse from pace maker, tachy arrhythmia. Antiarrhythmic Drugs: These are drugs used to prevent or treat irregularities of cardiac rhythm. The important cardiac arrhythmias are:  Atrial flutter (AFI)  Atrial fibrillation (AF)  Ventricular tachycardia (VT)  Ventricular fibrillation (VF)  Atrio-ventricular (A-V) block
Antiarrhythmic drugs Class Actions Drugs I Membrane stabilizing agents (Na+ channel blockers) Quinidine, Procainamide, Disopyramide, Lidocaine, Mexiletine, Propafenone, Flecainide etc. II Antiadrenergic agents (β blockers) Propranolol, Esmolol, Sotalol (also class III) III Agents widening AP (prolong repolarization and ERP) Amiodarone, Dronedarone, Dofetilide, Ibutilide IV Calcium channel blockers Verapamil, Diltiazem
Mechanism of action 1. Membrane stabilizing agents: Quinidine Quinidine block myocardial Na + channel & prevent Na+ enflux. Reduce the maximal rate of 0 phase depolarization & also decrease slope of phase-4 quinidine decrease the availability of Na+ channel as well as deals their reactivation Inhibit action potentials
2. Beta Blocker: Propranolol Propranolol is beta-adrenergic antagonist by nature they are sympathetic antagonist inhibit sympathetic tone & decrease heart rate Prolong the AV conduction inhibit phase- 4 Delayed action potentials
3. Ca++ channel blocker: verapamil Ca++ channel blocker are block the Ca++ channel in myocardium Verapamil it show the negative inotropic action interfere with Ca++ ion The most action of verapamil is prolongation of AV- noded ERP
4. Agent widening A.P.: Amiodorone Amiodorone block K+ ion channel in myocardial cell Diminish the outward K+ ion currect during repoarization of cardiac muscle cell Prolong the duration of action potential Prolong the ERP
Pharmacokinetics (lidocaine) Absorption: Lidocaine is inactive orally due to high first pass metabolism in liver. Distribution: Action of an i.v. bolus lasts only 10–20 min because of rapid redistribution. Metabolism: Metabolism of lidocaine is hepatic blood flow dependent. Excreation: It is hydrolysed, deethylated and conjugated; metabolites are excreted in urine
use Arrhythmia Atrial flutter (AFI) Atrial fibrillation (AF) Ventricular tachycardia (VT) Ventricular fibrillation (VF) Atrio-ventricular (A-V) block Adverse effects:  Fall in BP,  bradycardia and myocardial depression  Nausea, gastrointestinal upset
References • Tripathi KD, “Essentials of Medical Pharmacology” published by Jaypee Brothers Medical Publishers (P) Ltd, Seventh Edition: 2013, New Delhi, p.p. no-526-538.
Antiarrhythmic drugs